Sugi Predict

Sugi Predict / Compounds / SCHEMBL8950858

SCHEMBL8950858

SCHEMBL8950858

CC(C)(C)OC(=O)N1CCC[C@]1(C)CO

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 1/20 0.41
▸ GRIN2C Q14957 1/20 0.41
▸ CTSK P43235 1/20 0.40
▸ USP2 O75604 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NR1H2 P55055 1/20 0.36
▸ JAK3 P52333 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ CYP4F2 P78329 1/20 0.35
▸ CYP4A11 Q02928 1/20 0.35
▸ EPHX1 P07099 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL705582 1.00 GRIN2B (0.41) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2
SCHEMBL15425362 1.00 GRIN2B (0.41) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2
SCHEMBL20399337 0.95 CTSK (0.39) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2
SCHEMBL21530335 0.95 CTSK (0.39) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2
SCHEMBL21530334 0.95 CTSK (0.39) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2
SCHEMBL17818932 0.90 USP2 (0.39) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2
SCHEMBL27092782 0.89 GRIN2B (0.40) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2
SCHEMBL12424303 0.89 GRIN2B (0.41) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2
SCHEMBL10202327 0.89 GRIN2B (0.41) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2
SCHEMBL6922182 0.86 GRIN2B (0.43) GRIN2BGRIN2CCTSKUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079960-A Alkynyl quinazoline compounds — 2026-05-26 — — CN disclosed
US-12630562-B2 Piperidylurea compounds and methods of use thereof ARCUS BIOSCIENCES, INC. (US) 2026-05-19 — — US disclosed
EP-4013749-B1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-03-11 — — EP disclosed
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-19 — — US disclosed
US-20260042777-A1 PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-02-12 — — US disclosed
EP-4653438-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-11-26 — — EP disclosed
US-12435046-B2 Alkynyl quinazoline compounds BLACK DIAMOND THERAPEUTICS, INC. (US) 2025-10-07 — — US disclosed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 — — US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 — — WO disclosed
CN-119390683-A Alkynyl quinazoline compounds 黑钻治疗公司 2025-02-07 — — CN disclosed
US-8722727-B2 Antifungal agents Seynix, Inc. (US) 2014-05-13 — — US disclosed
EP-2326180-B1 ANTIFUNGAL AGENTS MERCK SHARP & DOHME (US) 2013-10-16 — — EP disclosed
US-8188085-B2 Antifungal agents MERCK SHARP & DOHME CORP. (US) 2012-05-29 — — US disclosed
US-8188085-B2 Antifungal agents MERCK SHARP & DOHME CORP. (US) 2012-05-29 — — US disclosed
US-20110224228-A1 ANTIFUNGAL AGENTS MERCK SHARP & DOHME CORP. (US) 2011-09-15 — — US disclosed
US-20110224228-A1 ANTIFUNGAL AGENTS MERCK SHARP & DOHME CORP. (US) 2011-09-15 — — US disclosed
US-20100113439-A1 Antifungal agents MERCK & CO., INC. (US) 2010-05-06 — — US disclosed
US-20100113439-A1 Antifungal agents MERCK & CO., INC. (US) 2010-05-06 — — US disclosed
WO-2010019206-A1 ANTIFUNGAL AGENTS MERCK SHARP & DOHME CORP. (US) 2010-02-18 — — WO disclosed
WO-2010019204-A1 ANTIFUNGAL AGENTS MERCK SHARP & DOHME CORP. (US) 2010-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224228-A1 ANTIFUNGAL AGENTS GMDS, GBA3, UGGT1 GRIN2B 4244/4885GRIN2C 4122/4885CTSK 1031/4885
US-12435046-B2 Alkynyl quinazoline compounds GLS, GLS2, MCL1 GRIN2B 1629/4885GRIN2C 844/4885CTSK 1534/4885
US-20100113439-A1 Antifungal agents GMDS, GBA3, UGGT1 GRIN2B 4281/4885GRIN2C 4196/4885CTSK 1149/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS GRIN2B 4557/4885GRIN2C 4405/4885CTSK 2693/4885
US-12630562-B2 Piperidylurea compounds and methods of use thereof CLIC1, HCCS, CNR1 GRIN2B 2991/4885GRIN2C 490/4885CTSK 2736/4885
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 GRIN2B 3016/4885GRIN2C 294/4885CTSK 888/4885
US-20260042777-A1 PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF CBR1, CLIC1, RER1 GRIN2B 2978/4885GRIN2C 751/4885CTSK 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.